Abstract:Cancer is a complicated illness that spreads indefinitely owing to epigenetic, genetic, and genomic alterations. Cancer cell multidrug susceptibility represents a severe barrier in cancer therapy. As a result, creating effective therapies requires a better knowledge of the mechanisms driving cancer development, progress, and resistance to medications. The human genome is predominantly made up of long non coding RNAs (lncRNAs), which are currently identified as critical moderators in a variety of biological functions. Recent research has found that changes in lncRNAs are closely related to cancer biology. The vascular endothelial growth factor (VEGF) signalling system is necessary for angiogenesis and vascular growth and has been related to an array of health illnesses, such as cancer. LncRNAs have been identified to alter a variety of cancer-related processes, notably the division of cells, movement, angiogenesis, and treatment sensitivity. Furthermore, lncRNAs may modulate immune suppression and are being investigated as possible indicators for early identification of cancer. Various lncRNAs have been associated with cancer development and advancement, serving as cancer-causing or suppressing genes. Several lncRNAs have been demonstrated through research to impact the VEGF cascade, resulting in changes in angiogenesis and tumor severity. For example, the lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) has been shown to foster the formation of oral squamous cell carcinoma and the epithelial-mesenchymal transition by stimulating the VEGF-A and Notch systems. Plasmacytoma variant translocation 1 (PVT1) promotes angiogenesis in non-small-cell lung cancer by affecting miR-29c and boosting the VEGF cascade. Furthermore, lncRNAs regulate VEGF production and angiogenesis by interacting with multiple downstream signalling networks, including Wnt, p53, and AKT systems. Identifying how lncRNAs engage with the VEGF cascade in cancer gives beneficial insights into tumor biology and possible treatment strategies. Exploring the complicated interaction between lncRNAs and the VEGF pathway certainly paves avenues for novel ways to detect better accurately, prognosis, and cure cancers. Future studies in this area could open avenues toward the creation of innovative cancer therapy regimens that enhance the lives of patients.

Getting to know ovarian cancer: Focusing on the effect of LncRNAs in this cancer and the effective signaling pathways

The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC)

Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications

Long Noncoding RNAs in Ovarian Cancer—Functions and Clinical Applications

LncRNA RAD51B-AS1 promotes the malignant biological behavior of ovarian cancer via upregulation of RAD51B

Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer

Long Non-Coding RNAs in Recurrent Ovarian Cancer: Theranostic Perspectives.

Identification of the Coregulated Mrna and Lncrna Functional Pathways in Ovarian Cancer Using LncRNAs2Pathways by Lncrnas Based on an Integrated Network Propagation

Comprehensive analyses of fatty acid metabolism-related lncRNA for ovarian cancer patients

The Role of Long Non-Coding RNAs in Ovarian Cancer Cells

The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian Cancer

Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes

WITHDRAWN: Comprehensive analyses of fatty acid metabolism-related lncRNA for ovarian cancer patients

HER2 Puzzle Pieces: Non-Coding RNAs as Keys to Mechanisms, Chemoresistance, and Clinical Outcomes in Ovarian Cancer

Potential Roles of Long Non-coding RNAs in Regulating Cell Proliferation, Invasion, and Metastasis in Ovarian Serous Cystadenocarcinoma

LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

Exploring the lncRNA-VEGF axis: Implications for cancer detection and therapy

Recent progress and the emerging role of lncRNAs in cancer drug resistance; focusing on signaling pathways

Identification of pathological grade and prognosis‐associated lncRNA for ovarian cancer